Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Riociguat

FDA-approved product (tablet, oral), marketed as Adempas, Riociguat.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Riociguat
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Hypertension
  • Idiopathic and/or familial pulmonary arterial hypertension
  • Pulmonary arterial hypertension
  • Pulmonary hypertension

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Antihypertensives for pulmonary arterial hypertension
FDA pharmacologic class
Soluble Guanylate Cyclase Stimulator FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA46.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli32.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae28.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis68.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Riociguat in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.4 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.3 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.8 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.7 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Riociguat with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Riociguat in Patients With Operable CTEPH Prior to Pulmonary Endarterectomy (PEA Bridging Study)

    NCT03273257 · start 2018-08-17

    Registered record
    Registry ID
    NCT03273257
    Conditions
    Chronic Thromboembolic Pulmonary Hypertension; CTEPH
    Interventions
    Riociguat; Placebo; Pulmonary endarterectomy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2018-08-17
    Completion
    2020-05-05
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Thromboembolic Pulmonary Hypertension; CTEPH
    InterventionRiociguat; Placebo; Pulmonary endarterectomy
    PhasePhase 2
    Registry statusTerminated

  • ADAMTSL4 in Idiopathic Pulmonary Hypertension and CTEPH

    NCT05478226 · start 2018-07-01

    Registered record
    Registry ID
    NCT05478226
    Conditions
    Pulmonary Hypertension
    Interventions
    drugs or BPA
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2018-07-01
    Completion
    2022-07-01
    Enrolment
    67

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary Hypertension
    Interventiondrugs or BPA
    PhaseNot recorded
    Registry statusCompleted

  • Treatment of Exercise-Induced Pulmonary Vascular Dysfunction After Pulmonary Thromboendarterectomy or Balloon Pulmonary Angioplasty

    NCT03409588 · start 2018-06-13

    Registered record
    Registry ID
    NCT03409588
    Conditions
    Chronic Thromboembolic Disease (CTED); Exercise Intolerance Post PEA Surgery
    Interventions
    Adempas
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2018-06-13
    Completion
    2026-01-26
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Thromboembolic Disease (CTED); Exercise Intolerance Post PEA Surgery
    InterventionAdempas
    PhasePhase 2
    Registry statusCompleted

  • Clinical Study to Investigate Effect of Macitentan on Riociguat Pharmacokinetics

    NCT03389321 · start 2018-01-09

    Registered record
    Registry ID
    NCT03389321
    Conditions
    Healthy Subjects
    Interventions
    Riociguat (Adempas); Macitentan (Opsumit)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2018-01-09
    Completion
    2018-02-06
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Subjects
    InterventionRiociguat (Adempas); Macitentan (Opsumit)
    PhasePhase 1
    Registry statusCompleted

  • A Multi-Center Study of Riociguat in Patients With Sickle Cell Diseases

    NCT02633397 · start 2017-04-11

    Registered record
    Registry ID
    NCT02633397
    Conditions
    Sickle Cell Disease
    Interventions
    Riociguat; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2017-04-11
    Completion
    2022-05-04
    Enrolment
    130

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSickle Cell Disease
    InterventionRiociguat; Placebo
    PhasePhase 2
    Registry statusCompleted

  • Riociguat rEplacing PDE-5i Therapy evaLuated Against Continued PDE-5i thErapy

    NCT02891850 · start 2017-01-11

    Registered record
    Registry ID
    NCT02891850
    Conditions
    Pulmonary Arterial Hypertension
    Interventions
    Riociguat (Adempas, BAY63-2521); Sildenafil; Tadalafil
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2017-01-11
    Completion
    2020-03-03
    Enrolment
    225

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary Arterial Hypertension
    InterventionRiociguat (Adempas, BAY63-2521); Sildenafil; Tadalafil
    PhasePhase 4
    Registry statusCompleted

  • Riociguat in Scleroderma Associated Digital Ulcers

    NCT02915835 · start 2016-09

    Registered record
    Registry ID
    NCT02915835
    Conditions
    Scleroderma; Digital Ulcers
    Interventions
    Riociguat; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2016-09
    Completion
    2018-07-24
    Enrolment
    17

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionScleroderma; Digital Ulcers
    InterventionRiociguat; Placebo
    PhasePhase 2
    Registry statusCompleted

  • A Long-term Extension Study of Riociguat in Patients With Symptomatic Pulmonary Arterial Hypertension.

    NCT02759419 · start 2016-06-16

    Registered record
    Registry ID
    NCT02759419
    Conditions
    Hypertension, Pulmonary
    Interventions
    Adempas (Riociguat, BAY63-2521)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2016-06-16
    Completion
    2025-09-15
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension, Pulmonary
    InterventionAdempas (Riociguat, BAY63-2521)
    PhasePhase 4
    Registry statusCompleted

  • Upfront Combination Pulmonary Arterial Hypertension Therapy

    NCT03809156 · start 2016-04-26

    Registered record
    Registry ID
    NCT03809156
    Conditions
    Pulmonary Hypertension
    Interventions
    Riociguat Oral Product
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2016-04-26
    Completion
    2021-01-31
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary Hypertension
    InterventionRiociguat Oral Product
    PhasePhase 4
    Registry statusUnknown

  • Interaction With HIV Antiretroviral Agents

    NCT02556268 · start 2016-02-23

    Registered record
    Registry ID
    NCT02556268
    Conditions
    HIV-DDI
    Interventions
    Riociguat (Adempas, BAY 63-2521); ATRIPLA; COMPLERA; STRIBILD; TRIUMEQ; Antiretroviral protease inhibitor
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2016-02-23
    Completion
    2016-12-07
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-DDI
    InterventionRiociguat (Adempas, BAY 63-2521); ATRIPLA; COMPLERA; STRIBILD +2 more
    PhasePhase 1
    Registry statusCompleted

  • Riociguat in Children With Pulmonary Arterial Hypertension (PAH)

    NCT02562235 · start 2015-10-29

    Registered record
    Registry ID
    NCT02562235
    Conditions
    Hypertension, Pulmonary
    Interventions
    Riociguat (Adempas, BAY63-2521)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2015-10-29
    Completion
    2027-08-03
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension, Pulmonary
    InterventionRiociguat (Adempas, BAY63-2521)
    PhasePhase 3
    Registry statusActive not recruiting

  • A Study to Understand the Treatment Patterns in Patients With Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension During a Switch of Treatment to Adempas in Real-life Clinical Practice

    NCT02545465 · start 2015-09-15

    Registered record
    Registry ID
    NCT02545465
    Conditions
    Hypertension, Pulmonary
    Interventions
    Riociguat (Adempas, BAY63-2521)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2015-09-15
    Completion
    2016-08-31
    Enrolment
    125

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension, Pulmonary
    InterventionRiociguat (Adempas, BAY63-2521)
    PhaseNot recorded
    Registry statusCompleted

  • Chronic Thrombo-embolic Pulmonary Hypertension: Classification and Long Term Outcome

    NCT02565030 · start 2015-02

    Registered record
    Registry ID
    NCT02565030
    Conditions
    Chronic Thromboembolic Pulmonary Hypertension; Idiopathic Pulmonary Arterial Hypertension
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2015-02
    Completion
    2021-10
    Enrolment
    1,200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Thromboembolic Pulmonary Hypertension; Idiopathic Pulmonary Arterial Hypertension
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis

    NCT02283762 · start 2015-01-15

    Registered record
    Registry ID
    NCT02283762
    Conditions
    Scleroderma, Systemic
    Interventions
    Riociguat (Adempas, BAY63-2521); Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2015-01-15
    Completion
    2019-03-28
    Enrolment
    121

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionScleroderma, Systemic
    InterventionRiociguat (Adempas, BAY63-2521); Placebo
    PhasePhase 2
    Registry statusCompleted

  • Early Signs of Efficacy Study With Riociguat in Adult Homozygous Delta F508 Cystic Fibrosis Patients

    NCT02170025 · start 2014-09-30

    Registered record
    Registry ID
    NCT02170025
    Conditions
    Cystic Fibrosis
    Interventions
    Riociguat (Adempas, BAY63-2521); Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2014-09-30
    Completion
    2017-09-22
    Enrolment
    21

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCystic Fibrosis
    InterventionRiociguat (Adempas, BAY63-2521); Placebo
    PhasePhase 2
    Registry statusTerminated